On basic definitions of unified fracture mechanics terminology

The adoption of unified fracture mechanics terminology (UFMT) will promote efficient communication between specialists in different fields of fracture research, harmonization of national and international standards relating to fracture mechanics, and last but not least improvement of the existing methodology for teaching and education in fatigue and fracture. In this paper the definitions of some basic and related terms included in different standards on fracture mechanics terminology are confronted with one another. Alternative definitions of the same terms are offered. By this strategy the author tries to show that the definitions of basic and related terms appropriate for the UFMT should emerge as a consequence of harmonizing a crack model with an actual crack and then both taken together with a fracture model, laboratory test methods, and failure assessment codes.Published in Problemy Prochonsti, No. 1, pp. 17–29, January, 1996.This paper is published as a matter of discussion.     

New high-efficiency low-waste technology at the Vyksa Metallurgical Plant for operating metallurgical equipment with the use of Kompaks® monitoring systems

Introduction of the BER? KOMPAKS® automated system at the Vyksa Metallurgical Plant to safely and efficiently manage the operation of the plant’s equipment has allowed the facility to begin operating that equipment based on real-time evaluations of its actual physical condition. Introduction of the new system has also allowed better coordination of repair-scheduling with ongoing production operations, significantly improved the reliability and readiness of the equipment for operation at 100% capacity, completely eliminated the human factor from the process of monitoring the condition of equipment, and made it possible to check the quality and timeliness of equipment maintenance and repair work so as to ensure safe, efficient operation of the entire production complex.     

Nucleation and growth of a macrocrack in tension and compression

Conclusions The general approach to analysis of the processes of nucleation and growth of radial separation macrocracks from the surface of a circular hole in sheets deformed in tension and compression was used to obtain new relations for calculating the characteristic values of compressive and tensile loads. The calculated results are in satisfactory agreement with the results of tests on sheets. At the same time, we detected unexpected fundamentally important aspects of the problem of brittle failure by separation.Firstly, it is justified to assume that the length of the region of the strong effect of the free surface of the hole on the state of the zone of development of the failure process in compression can be an order of magnitude higher than that in tensile loading. Secondly, with an increase of the distance of the crack tips from the hole the resistance of the material to failure in compressive loading gradually increases from the value close to minimum, at which k = 0, to its maximum value at k=-. If both these claims are valid, in future it would be necessary to revise greatly the methodology, results, and conclusions of a large number of investigations of brittle failure in compression, partially, in tension.Translated from Fiziko-Khimicheskaya Mekhanika Materialov, Vol. 27, No. 5, pp. 62–66, September–October, 1991.     

Overview on Recent Developments of Bondcoats for Plasma-Sprayed Thermal Barrier Coatings

The performance of MCrAlY (M = Ni, Co) bondcoats for atmospheric plasma-sprayed thermal barrier coatings (APS-TBCs) is substantially affected by the contents of Co, Ni, Cr, and Al as well as minor additions of Y, Hf, Zr, etc., but also by manufacturing-related properties such as coating thickness, porosity, surface roughness, and oxygen content. The latter properties depend in turn on the exact technology and set of parameters used for bondcoat deposition. The well-established LPPS process competes nowadays with alternative technologies such as HVOF and APS. In addition, new technologies have been developed for bondcoats manufacturing such as high-velocity APS or a combination of HVOF and APS for application of a flashcoat. Future developments of the bondcoat systems will likely include optimization of thermal spraying methods for obtaining complex bondcoat roughness profiles required for extended APS-TBC lifetimes. Introduction of the newest generation single-crystal superalloys possessing low Cr and high Al and refractory metals (Re, Ru) contents will require definition of new bondcoat compositions and/or multilayered bondcoats to minimize interdiffusion issues. The developments of new bondcoat compositions may be substantially facilitated using thermodynamic–kinetic modeling, the vast potential of which has been demonstrated in recent years.     

The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels

Recently, we demonstrated that administration of the orally active iron chelating agent deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one (L1)) at 6-hour intervals results in significantly greater urinary iron excretion than that induced during administration of the drug at 12-hour intervals. That study was conducted in thalassemia patients, all of whom had received a packed red cell transfusion of 15 cc/kg. 72 hours prior to evaluation of urinary iron excretion, at a time when endogenous erythropoiesis would be expected to be at its lowest. In clinical practice however, thalassemia patients, suppression of endogenous erythropoiesis is not sustained between transfusions. We set out to determine the influence that administration of deferiprone has on urinary iron excretion at lower hemoglobin concentrations, immediately prior to transfusion. We hypothesized that hemoglobin levels will affect the ability of deferiprone to chelate iron. Ten regularly transfused patients with homozygous beta-thalassemia (HBT) aged mean +/- SD, 20.9 +/- 4.7, range 13 - 27 years, receiving long-term therapy with deferiprone, were treated with deferiprone 75 mg/kg/day, administered every 6 hours (or every 12 hours) for 72 hours immediately prior to a blood transfusion in the first month. One month later each patient received the other of the 2 dosing regimens for 72 hours immediately prior to transfusion. The deferiprone-induced 24-hour urinary iron excretion was similar during both dosing regimens; 0.56 +/- 0.45 mg/kg when L1 was given every 6 hours and 0.48 +/- 0.52 mg/kg when L1 was administered every 12 hours (p = 0.79). However, the calculated 24-hour area under the plasma concentration-time curve (AUC0-24) of deferiprone was significantly lower when deferiprone was administered at 6-hour intervals (6,762.8 +/- 1,601.6 mg*min/l), than that observed when deferiprone was administered every 12 hours (8,250.1 +/- 1,235.7 mg*min/l) (p = 0.04). The pharmacokinetics of deferiprone when administered immediately prior to transfusions are different from those following transfusions. More studies assessing total body iron excretion are needed to determine the contribution of the fecal route in iron excretion.     

The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults

OBJECTIVE: Growth hormone (GH) replacement therapy in hypopituitary adults is associated with sodium and water retention. The underlying mechanisms are incompletely understood and a possible contribution of altered cortisol metabolism or action has not been evaluated. We have investigated the effect of GH replacement therapy on cortisol metabolism, cortisol binding globulin and in-vitro glucocorticoid sensitivity in a group of adult hypopituitary patients. DESIGN AND PATIENTS: We studied 19 adult hypopituitary patients (18 adult onset, M:F, 6:13), who were receiving conventional hydrocortisone (16 patients), thyroxine (14 patients), triiodothyronine (1 patient), sex steroid (9 patients), human chorionic gonadotrophin (1 patient) or desmopressin (6 patients) replacement during a 6-month, double blind controlled trial of GH therapy (active:placebo, 8:11) followed by a 6-month open phase of GH (mean dose: 0.2 IU/kg/week, range 0.051-0.27) and after a 6-week washout phase following discontinuation of GH therapy. MEASUREMENTS: Twenty-four-hour urine free cortisol, cortisol metabolites (CoM), ratio 11-hydroxy/11-oxo CoM (F/E) and ratio 5 alpha/beta tetrahydrocortisol were measured at 6 months, 12 months and after the 6 week washout phase. Serum cortisol binding globulin was measured basally, at 6 months, 12 months and after washout. Glucocorticoid sensitivity was determined in lymphocyte preparations from 8 patients, during GH therapy and after washout, using an in-vitro technique dependent on dexamethasone suppression of phytohaemagglutinin-stimulated thymidine incorporation into DNA. Plasma renin activity and aldosterone were measured after 6-12 months GH therapy and after washout. RESULTS: After 6 months of GH, in patients on hydrocortisone (n = 9), there were significant decreases in CoM (mean decrement 21%, P < 0.01), F/E (mean decreased from 1.27 to 1.0, P = 0.04; reference range 0.33-1.29) and 5 alpha/5 beta tetrahydrocortisol (mean decreased from 0.67 to 0.48, P = 0.01) and a subsequent increase after washout. Patients not on hydrocortisone (n = 2) demonstrated a normal basal F/E falling by 25% on GH therapy but no change in CoM. During 12 months of GH therapy, patients on hydrocortisone (n = 7) demonstrated a further trend to decrement in CoM (P = 0.09) which reversed after washout (P = 0.04). Urine free cortisol tended to fall during GH therapy and increased significantly following washout after 12 months treatment (P < 0.02). Serum cortisol binding globulin decreased by 20% (P < 0.05) during 12 months GH treatment but remained within the reference range. In-vitro studies demonstrated a trend to reduced glucocorticoid sensitivity on GH therapy; the maximum inhibition of phytohaemagglutinin by dexamethasone tended to be less on GH therapy (P = 0.052) and was also lower than in 29 normal volunteers (P < 0.05). There were no significant changes in plasma renin but there was a small increment in aldosterone in recumbent patients (P = 0.04) during the open phase of GH therapy in the placebo arm. CONCLUSIONS: GH therapy in hypopituitary adults is associated with an apparent reduction in availability of administered hydrocortisone as measured by urine cortisol metabolites and urine free cortisol. This effect is unlikely to be clinically significant except possibly in ACTH deficient subjects on suboptimal hydrocortisone replacement. The changes in F/E suggest that GH may directly or indirectly modulate the activity of 11 beta-hydroxysteroid dehydrogenase. The apparent decrease in glucocorticoid sensitivity during GH therapy, demonstrated in vitro, merits further investigation.     

Anti-D in a D-positive renal transplant patient

PURPOSE: We report a case of postoperative reparalysis in the recovery room, following nebulized epinephrine. The patient was pharmacologically reversed with edrophonium after paralysis with rocuronium. CLINICAL FINDINGS: A 12-yr-old girl developed postoperative reparalysis following the intraoperative administration of rocuronium. A total of 0.92 mg.kg-1 rocuronium was administered. After surgery, pharmacological reversal was achieved with 20 mg edrophonium with 0.15 mg atropine sulfate iv 35 min after the last administration of rocuronium. Muscular relaxation was monitored using an ulnar peripheral nerve stimulator (PNS). After reversal, a full train-of-four and sustained tetanus at 50 Hz were present. In the recovery room, following nebulized epinephrine, the patient became apneic. The patient was paralyzed and an ulnar PNS demonstrated only one faint twitch. The paralysis was reversed with 1.5 mg neostigmine with 0.3 mg glycopyrrolate. CONCLUSION: Postoperative reparalysis following rocuronium may be a cause of postoperative respiratory distress. The definitive diagnosis is made using PNS and observing the response to pharmacological reversal. Nebulized epinephrine may have a previously undescribed role in the development of postoperative reparalysis.     

Effect of Nb Addition on Oxidation Mechanisms of High Cr Ferritic Steel in Ar–H2–H2O

High chromium ferritic steels are being used as construction materials for interconnects in solid oxide electrolysis cells (SOEC). Addition of niobium in the range of a few tenths of a percent is suitable for increasing the high-temperature creep strength of this type of ferritic steel. In the present work, the high-temperature isothermal oxidation behavior of a niobium containing ferritic steel at 800 °C was investigated in Ar–4%H₂–4%H₂O gas simulating the service environment in an SOEC (cathode side) and compared with that of a Nb-free counterpart alloy. Gravimetric data were correlated with the results from microstructural analyses using, among others, scanning and transmission electron microscopy as well as glow discharge optical emission spectroscopy. Atom probe tomography was used for obtaining atomic-scale insight into the segregation processes in external oxides and their interfaces. The oxidation rate was substantially higher for the Nb-containing than for the Nb-free alloy. Both alloys formed double-layered oxide scales consisting of inner chromia and outer MnCr₂O₄ spinel. Additionally, a thin layer of rutile-type Nb(Ti,Cr)O₂ oxide of 200–300 nm thickness was observed at the scale–alloy interface in the Nb-containing steel. Nb addition to the alloy led to its segregation at chromia grain boundaries which affected the diffusion of Cr and other solute species such as Ti, Mn and Si.